Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial ... commercial insurance. NovoLog and Novo Nordisk’s other rapid-acting insulin follow-on Fiasp are ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog ... and 10 mL multiple-dose vial versions of the drug.

It is the first biosimilar of a rapid-acting insulin ... dose vial should be administered by subcutaneous injection within five to 10 minutes before the start of a meal. NovoLog is also available ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart ... at no more than $30 per vial and no more than $55 for a ...

injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% ...

Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin ... multiple-dose vial. Merilog is the third ...

The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. Merilog is a ...